Literature DB >> 7619751

Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients.

M Tomamichel1, C Sessa, S Herzig, J de Jong, O Pagani, Y Willems, F Cavalli.   

Abstract

BACKGROUND: The process by which patients are informed and their consent is obtained in phase I trials has thus far been only marginally studied. Since 1986 we have followed an oral procedure, consisting of three consecutive conversations in which the investigator responsible for phase I studies, the research nurse and the patients' relatives and/or friends also participate, followed by the patients signing of a written consent form. It is required that six items of information considered essential by our staff be conveyed to patients by the responsible investigator. Meerwein's model, which defines three main dimensions of the informing process (the information itself, the emotional and interactive aspects), has been studied to ascertain whether it can be applied to evaluate the quality of the information proffered.
METHODS: Thirty-two conversations were taped, transcribed and evaluated by one psychiatrist and one psychologist. A quantitative analysis of information was performed by calculating the number of patients to whom the essential items of information had been conveyed. The qualitative analysis was performed by rating on a five-point scoring system, from 1 (very bad) to 5 (excellent), the three dimensions of the informing process for each patient and by calculating for each dimension the mean score of the constituent items.
RESULTS: Complete information about the characteristics of the phase I drug and the modalities of the treatment and follow up was given to almost 80% of the patients. All but one of the items of the information dimension scored 3.5 or higher, with the one related to the assessment by the doctor of the patient's understanding at the end of the consultation scoring less than 3 in 53% of the patients. All items of the emotional dimension scored higher than 3.5. Greater difficulty was encountered by the physician with the interactive dimension, the lowest mean scores being reported on the items related to the doctor's awareness of the indirectly expressed anxieties of the patients. In 71% of the consultations the three dimensions of information scored more than 3 and balanced one another, indicating a successful consultation by the Meerwein model.
CONCLUSIONS: The informed consent procedure applied was satisfactory from a quantitative point of view, and the main items of information were acceptable to the patients. Meerweins's model proved to be applicable and useful for identifying pitfalls in communication. Greater attention should be paid to the indirect messages and implied criticisms of the patients to improve their participation in decision making. Physicians should become more skillful in providing adequate information and improve their methods of communication.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Substances:

Year:  1995        PMID: 7619751     DOI: 10.1093/oxfordjournals.annonc.a059185

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  19 in total

Review 1.  Communication and informed consent in phase 1 trials: a review of the literature.

Authors:  A C Cox; L J Fallowfield; V A Jenkins
Journal:  Support Care Cancer       Date:  2006-01-28       Impact factor: 3.603

Review 2.  Ethical issues in the development of new agents.

Authors:  C K Daugherty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Communication and phase 1 clinical trial recruitment.

Authors:  Martin H N Tattersall
Journal:  Support Care Cancer       Date:  2006-01-10       Impact factor: 3.603

4.  Discussing molecular testing in oncology care: Comparing patient and physician information preferences.

Authors:  Ana P M Pinheiro; Rachel H Pocock; Jeffrey M Switchenko; Margie D Dixon; Walid L Shaib; Suresh S Ramalingam; Rebecca D Pentz
Journal:  Cancer       Date:  2017-01-31       Impact factor: 6.860

5.  Measuring the process and quality of informed consent for clinical research: development and testing.

Authors:  Elizabeth Gross Cohn; Haomiao Jia; Winifred Chapman Smith; Katherine Erwin; Elaine L Larson
Journal:  Oncol Nurs Forum       Date:  2011-07       Impact factor: 2.172

Review 6.  Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009.

Authors:  Valerie A Jenkins; John L Anderson; Lesley J Fallowfield
Journal:  Support Care Cancer       Date:  2010-03-04       Impact factor: 3.603

7.  Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Authors:  Fay J Hlubocky; Greg A Sachs; Eric R Larson; Halla S Nimeiri; David Cella; Kristen E Wroblewski; Mark J Ratain; Jeffery M Peppercorn; Christopher K Daugherty
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

8.  Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Authors:  Fay J Hlubocky; Nancy E Kass; Debra Roter; Susan Larson; Kristen E Wroblewski; Jeremy Sugarman; Christopher K Daugherty
Journal:  J Oncol Pract       Date:  2018-05-22       Impact factor: 3.840

9.  Development and testing of a tool to assess patient preferences for phase I clinical trial participation.

Authors:  Rebecca D Pentz; Kristopher A Hendershot; Louisa Wall; Taylor E White; Susan K Peterson; Cheryl B Thomas; Jennifer McCormick; Michael J Green; Colleen Lewis; Zachary Luke Farmer; Fay J Hlubocky; Tehseen Dossul; Margie D Dixon; Yuan Liu; Jeffrey M Switchenko; Carolina Salvador; Taofeek K Owonikoko; R Donald Harvey; Fadlo R Khuri
Journal:  Psychooncology       Date:  2014-12-19       Impact factor: 3.894

10.  Can consultation skills training change doctors' behaviour to increase involvement of patients in making decisions about standard treatment and clinical trials: a randomized controlled trial.

Authors:  P Butow; R Brown; J Aldridge; I Juraskova; P Zoller; F Boyle; M Wilson; J Bernhard
Journal:  Health Expect       Date:  2014-06-30       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.